Halaby Rim, Popma Christopher J, Cohen Ander, Chi Gerald, Zacarkim Marcelo Rodrigues, Romero Gonzalo, Goldhaber Samuel Z, Hull Russell, Hernandez Adrian, Mentz Robert, Harrington Robert, Lip Gregory, Peacock Frank, Welker James, Martin-Loeches Ignacio, Daaboul Yazan, Korjian Serge, Gibson C Michael
Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, East Campus, RW 459, Boston, MA, 02215, USA.
J Thromb Thrombolysis. 2015 Jan;39(1):55-9. doi: 10.1007/s11239-014-1101-6.
D-Dimer is a biomarker of fibrin formation and degradation. While a D-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated D-dimer with adverse outcomes has received far less emphasis. An elevated D-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated D-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the D-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.
D - 二聚体是纤维蛋白形成和降解的生物标志物。虽然正常范围内的D - 二聚体用于排除临床静脉血栓栓塞症(VTE)可能性较低的患者的深静脉血栓形成和肺栓塞诊断,但D - 二聚体升高与不良结局的预后关联受到的关注要少得多。D - 二聚体升高与新发VTE、复发性VTE和死亡率增加独立相关。在广泛的疾病状态下,D - 二聚体升高是死亡率增加和随后发生VTE的独立相关因素。因此,D - 二聚体升高的内科疾病患者构成一个高危亚组,在此亚组中对抗血栓治疗的疗效和安全性进行前瞻性评估是必要的。